Kalaris Therapeutics Appoints Liisa Bayko CFO
Kalaris Therapeutics, Inc. (Nasdaq: KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced
Kalaris hired a new money manager (CFO) to help run the company's finances as it develops new medicines for eye diseases. When a company picks an experienced leader for an important job, it can mean the company is getting more organized and ready for growth.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.